For Founders & Execs
Assess your device's readiness to reach key milestones based on historical patterns from our proprietary database.
How It Works
Input your device parameters. Our proprietary analysis framework benchmarks your device against documented outcomes to assess readiness at each milestone.
Readiness for 510(k), De Novo, or PMA approval based on your regulatory strategy and demonstrated clinical evidence.
Readiness to generate initial revenue based on your market entry strategy and competitive landscape.
Readiness for reimbursement policy coverage based on your category and evidence.
Readiness to cross the adoption inflection point with physicians based on clinical adoption barriers and competitive context.
Projected pathway to profitability based on your market size assumptions, manufacturing costs, and unit economics.
Risk factors that most commonly derail scaling in your category and your mitigation strategy.
Sample Output
A redacted example showing how a device's risk profile evolves across key milestones.
Redacted example — Orthopedic implant company, 18-month assessment window. Shaded area represents confidence interval.
Sample Insight
Devices in the orthopedic implant category that lack a reimbursement strategy at 510(k) submission face materially higher profitability risk than those with payer engagement already underway — a pattern our comparable cohort surfaces.
Pattern Match
This company's pre-clearance profile most closely resembles 3 successful exits and 2 documented failures in our database. The differentiating factor: manufacturing scalability planning initiated before first commercial sale.
Your Vantage Index isn't static. As you clear FDA hurdles, your regulatory risk drops — but commercial risk often increases as you face reimbursement, adoption, and scaling challenges for the first time. Trajectory analysis tracks how each of the proprietary framework categories shifts as you progress, so you're always focused on the risks that matter now, not the ones you've already addressed.
Built on Our Framework
Trajectory analysis is built on our proprietary framework and grounded in documented device outcomes. We assess your device across all proprietary framework categories, identify readiness gaps at each milestone, and provide concrete recommendations for improvement.
Cohort-anchored differentiator analysis: Our proprietary framework risk-ranks medical devices by the risk factors most likely to be material at their stage, based on retrospective analysis of 800+ outcome-labeled biomedical companies in our proprietary cohort substrate, growing with every engagement.
Get a data-driven assessment of your path to major milestones. Schedule a consultation to discuss your device and what we're seeing in your category.
In a 20-minute call, we'll give you preliminary insights on your device's key risk categories.